Baxter Theranova: More Middle Molecules, Less Albumin Loss
Baxter’s new dialyzer mimics the function of natural kidneys more closely, removing more middle molecules with no replacement fluid needed—and minimal loss of vital albumin. The new expanded hemodialysis (HDx) therapy has been tested in the UK, where it reduced beta-2 microglobulin levels by more than 11%
Read the full article » | Posted 12/14/2017
Related Articles
- Overlook Medical Center Rides a Wavelinq for Non-Surgical Dialysis Access Posted 03/12/2019
- Made-To-Order Human Kidneys? Posted 03/12/2019
- Ontario’s Qidni Labs is a New Player in Kidney Innovation Posted 02/14/2019
- AWAK PD Device Receives FDA Breakthrough Device Status Posted 01/11/2019
- Catch the Easy Access Wave Posted 01/11/2019